30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Healthcare Equipment & Supplies

AngioDynamics Inc (ANGO)

Track

The most recent insider trading activity occurred on October 21, 2025, with a significant BUY transaction by SVP, Chief Legal Officer Lawrence T. Weiss. Prior to this, President and CEO James C. Clemmer and EVP and CFO Stephen A. Trowbridge also made substantial BUY transactions in October 2025. These recent BUYs by key executives represent the most notable insider trading pattern.
Stock chart
Ticker: ANGO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Weiss Lawrence T
SVP, Chief Legal Officer
1 purchase — total 118,100 USD
Buy 21 Oct 2025
Value US$3,806,127.12 | Price 375.17 | Shares 97,733
Buy 13 Oct 2025
Value US$4,069,008.71 | Price 365.96 | Shares 45,961
Buy 9 Oct 2025
Value US$111,500.00 | Price 11.15 | Shares 10,000
Sale 16 Jan 2025
Value US$49,978.60 | Price 12.31 | Shares 4,060
Proposed sale 16 Jan 2025
Value US$49,978.61 | Price 12.31 | Shares 4,060
Buy 10 Oct 2024
Value US$608.00 | Price 6.08 | Shares 100
Buy 8 Oct 2024
Value US$9,962.00 | Price 5.86 | Shares 1,700
Buy 7 Oct 2024
Value US$4,677.12 | Price 6.09 | Shares 768
Buy 7 Oct 2024
Value US$120,600.00 | Price 6.03 | Shares 20,000
Buy 8 Apr 2024
Value US$67,000.00 | Price 6.70 | Shares 10,000
Sale 31 Jan 2023
Value US$59,997.35 | Price 12.95 | Shares 4,633
Buy 12 Oct 2022
Value US$14,967.06 | Price 13.82 | Shares 1,083
Buy 10 Oct 2022
Value US$150,000.00 | Price 15.00 | Shares 10,000
Sale 29 Jul 2022
Value US$112,200.00 | Price 22.44 | Shares 5,000
Sale 28 Apr 2022
Value US$78,831.72 | Price 22.44 | Shares 3,513
Sale 12 Apr 2022
Value US$30,214.74 | Price 23.26 | Shares 1,299
Sale 11 Apr 2022
Value US$142,623.00 | Price 23.00 | Shares 6,201
Buy 12 Jan 2022
Value US$22,640.00 | Price 22.64 | Shares 1,000
Buy 11 Jan 2022
Value US$228,400.00 | Price 22.84 | Shares 10,000
Sale 20 Oct 2021
Value US$97,727.18 | Price 27.97 | Shares 3,494
Sale 15 Oct 2021
Value US$335,040.00 | Price 27.92 | Shares 12,000
Sale 5 Oct 2021
Value US$291,808.20 | Price 27.15 | Shares 10,748
Sale 14 Apr 2021
Value US$83,755.00 | Price 23.93 | Shares 3,500
Sale 20 Jan 2021
Value US$120,445.00 | Price 18.53 | Shares 6,500
Buy 11 Aug 2020
Value US$9,501.94 | Price 9.38 | Shares 1,013
Buy 31 Jul 2020
Value US$330,400.00 | Price 8.26 | Shares 40,000
Buy 25 Oct 2019
Value US$212,850.00 | Price 14.19 | Shares 15,000
Sale 16 Jul 2019
Value US$292,792.50 | Price 21.45 | Shares 13,650
Sale 7 Nov 2018
Value US$41,746.67 | Price 21.53 | Shares 1,939
Sale 15 Nov 2017
Value US$446,492.61 | Price 16.29 | Shares 27,409
Buy 24 Jul 2017
Value US$5,056.00 | Price 16.00 | Shares 316
Buy 21 Jul 2017
Value US$78,950.00 | Price 15.79 | Shares 5,000
Buy 21 Jul 2017
Value US$78,600.00 | Price 15.72 | Shares 5,000
Buy 20 Jul 2017
Value US$312,800.00 | Price 15.64 | Shares 20,000
Sale 12 Apr 2017
Value US$6,146,944.00 | Price 16.00 | Shares 384,184
Sale 12 Apr 2017
Value US$8,141,904.00 | Price 16.00 | Shares 508,869
Sale 12 Apr 2017
Value US$23,311,152.00 | Price 16.00 | Shares 1,456,947
Sale 12 Apr 2017
Value US$6,146,944.00 | Price 16.00 | Shares 384,184
Sale 12 Apr 2017
Value US$8,141,904.00 | Price 16.00 | Shares 508,869
Sale 12 Apr 2017
Value US$23,311,152.00 | Price 16.00 | Shares 1,456,947
Sale 18 Nov 2016
Value US$8,488,352.32 | Price 15.68 | Shares 541,349
Sale 18 Nov 2016
Value US$24,303,137.60 | Price 15.68 | Shares 1,549,945
Sale 18 Nov 2016
Value US$8,488,352.32 | Price 15.68 | Shares 541,349
Sale 18 Nov 2016
Value US$24,303,137.60 | Price 15.68 | Shares 1,549,945
Sale 5 Aug 2016
Value US$7,123,068.68 | Price 14.62 | Shares 487,214
Sale 5 Aug 2016
Value US$5,377,762.32 | Price 14.62 | Shares 367,836
Sale 5 Aug 2016
Value US$20,394,169.00 | Price 14.62 | Shares 1,394,950
Sale 5 Aug 2016
Value US$6,991,488.68 | Price 14.62 | Shares 478,214
Sale 5 Aug 2016
Value US$5,377,762.32 | Price 14.62 | Shares 367,836
Sale 5 Aug 2016
Value US$20,394,169.00 | Price 14.62 | Shares 1,394,950
Sale 6 May 2016
Value US$43,183.48 | Price 12.31 | Shares 3,508
Sale 25 Apr 2016
Value US$29,719.20 | Price 12.18 | Shares 2,440
Sale 21 Apr 2016
Value US$129,465.00 | Price 12.33 | Shares 10,500
Sale 13 Feb 2015
Value US$335,393.00 | Price 18.53 | Shares 18,100
Sale 20 Oct 2014
Value US$51,547.74 | Price 15.63 | Shares 3,298
Sale 14 Nov 2013
Value US$67,610.95 | Price 15.46 | Shares 4,373
Sale 13 Nov 2013
Value US$36,841.58 | Price 15.40 | Shares 2,392
Buy 18 Oct 2013
Value US$75,990.00 | Price 15.20 | Shares 5,000
Sale 17 Oct 2013
Value US$301,200.00 | Price 15.06 | Shares 20,000
Buy 22 Jul 2013
Value US$32,400.00 | Price 12.00 | Shares 2,700
Buy 12 Mar 2013
Value US$108,000.00 | Price 10.80 | Shares 10,000
Buy 12 Mar 2013
Value US$376,600.00 | Price 10.76 | Shares 35,000
Buy 12 Mar 2013
Value US$431,200.00 | Price 10.78 | Shares 40,000
Buy 12 Mar 2013
Value US$49,772.00 | Price 10.82 | Shares 4,600
Buy 14 Feb 2013
Value US$24,332.00 | Price 12.17 | Shares 2,000
Buy 11 Jan 2013
Value US$31,276.80 | Price 11.58 | Shares 2,700
Buy 5 Nov 2012
Value US$10,560.00 | Price 10.56 | Shares 1,000
Sale 5 Nov 2012
Value US$32,737.60 | Price 10.36 | Shares 3,160
Buy 17 Jul 2012
Value US$23,340.00 | Price 11.67 | Shares 2,000
Sale 16 May 2012
Value US$25,827.36 | Price 12.42 | Shares 2,080
Buy 12 Apr 2012
Value US$47,280.00 | Price 11.82 | Shares 4,000
Buy 11 Apr 2012
Value US$31,635.90 | Price 11.72 | Shares 2,700
Buy 10 Apr 2012
Value US$11,397.00 | Price 11.40 | Shares 1,000
Buy 9 Apr 2012
Value US$23,596.00 | Price 11.80 | Shares 2,000
Buy 9 Apr 2012
Value US$59,094.00 | Price 11.82 | Shares 5,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-22 2025-10-21 B Purchase
0.9
Weiss Lawrence T

SVP, Chief Legal Officer

Officer
97,733 -36.5%
375.17
US$3,806,127 		97,733 -36.5% 375.17 US$3,806,127
2025-10-14 2025-10-13 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
45,961 -11.8%
365.96
US$4,069,009 		45,961 -11.8% 365.96 US$4,069,009
2025-10-09 2025-10-09 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
85,365 +12.2%
93.63
US$48,238 		85,365 +12.2% 93.63 US$48,238
2025-01-17 2025-01-16 S Sale
3.3
Nighan Warren JR

SVP Quality and Regulatory

Officer
4,060 -8.8%
12.31
US$49,979 		4,060 -8.8% 12.31 US$49,979
2025-01-16 2025-01-16 PrS Proposed sale
3.3
Nighan Warren JR

Officer

Officer
4,060
12.31
US$49,979 		4,060 12.31 US$49,979
2024-10-10 2024-10-10 B Purchase
3.3
Nighan Warren JR

SVP Quality and Regulatory

Officer
100 +0.2%
6.08
US$608 		100 +0.2% 6.08 US$608
2024-10-08 2024-10-08 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,700 +1.0%
5.86
US$9,962 		1,700 +1.0% 5.86 US$9,962
2024-10-10 2024-10-07 B Purchase
3.3
Nighan Warren JR

SVP Quality and Regulatory

Officer
768 +1.7%
6.09
US$4,677 		768 +1.7% 6.09 US$4,677
2024-10-08 2024-10-07 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
20,000 +3.0%
6.03
US$120,600 		20,000 +3.0% 6.03 US$120,600
2024-04-08 2024-04-08 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +1.9%
6.70
US$67,000 		10,000 +1.9% 6.70 US$67,000
2023-02-01 2023-01-31 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
4,633 -19.4%
12.95
US$59,997 		4,633 -19.4% 12.95 US$59,997
2022-10-12 2022-10-12 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,083 +1.2%
13.82
US$14,967 		1,083 +1.2% 13.82 US$14,967
2022-10-11 2022-10-10 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +2.3%
15.00
US$150,000 		10,000 +2.3% 15.00 US$150,000
2022-08-01 2022-07-29 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
5,000 -17.3%
22.44
US$112,200 		5,000 -17.3% 22.44 US$112,200
2022-05-02 2022-04-28 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,513 -13.3%
22.44
US$78,832 		3,513 -13.3% 22.44 US$78,832
2022-04-13 2022-04-12 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
1,299 -1.6%
23.26
US$30,215 		1,299 -1.6% 23.26 US$30,215
2022-04-13 2022-04-11 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
6,201 -7.2%
23.00
US$142,623 		6,201 -7.2% 23.00 US$142,623
2022-01-12 2022-01-12 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,000 +1.3%
22.64
US$22,640 		1,000 +1.3% 22.64 US$22,640
2022-01-12 2022-01-11 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +2.6%
22.84
US$228,400 		10,000 +2.6% 22.84 US$228,400
2021-10-21 2021-10-20 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,494 -11.7%
27.97
US$97,727 		3,494 -11.7% 27.97 US$97,727
2021-10-18 2021-10-15 S Sale
2.4
Centea Scott

Sr. VP/GM, Global VIT

Officer
12,000 -20.6%
27.92
US$335,040 		12,000 -20.6% 27.92 US$335,040
2021-10-06 2021-10-05 S Sale
1.6
Campbell Chad Thomas

SVP/GM, Vascular Access

Officer
10,748 -25.3%
27.15
US$291,808 		10,748 -25.3% 27.15 US$291,808
2021-04-15 2021-04-14 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,500 -15.5%
23.93
US$83,755 		3,500 -15.5% 23.93 US$83,755
2021-01-21 2021-01-20 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
6,500 -7.7%
18.53
US$120,445 		6,500 -7.7% 18.53 US$120,445
2020-08-12 2020-08-11 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,013 +1.7%
9.38
US$9,502 		1,013 +1.7% 9.38 US$9,502
2020-08-03 2020-07-31 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
40,000 +13.2%
8.26
US$330,400 		40,000 +13.2% 8.26 US$330,400
2019-10-28 2019-10-25 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
15,000 +6.1%
14.19
US$212,850 		15,000 +6.1% 14.19 US$212,850
2019-07-18 2019-07-16 S Sale
3.2
Gould Kevin J
13,650 -19.8%
21.45
US$292,792 		13,650 -19.8% 21.45 US$292,792
2018-11-08 2018-11-07 S Sale Greiner Michael

EVP and CFO

Officer
1,939 -8.6%
21.53
US$41,747 		1,939 -8.6% 21.53 US$41,747
2017-11-17 2017-11-15 S Sale Richard Stark

SVP, GM - Oncology
27,409 -56.9%
16.29
US$446,493 		27,409 -56.9% 16.29 US$446,493
2017-07-25 2017-07-24 B Purchase REED JAN STERN Non-Executive Director
316 +inf%
16.00
US$5,056 		316 +inf% 16.00 US$5,056
2017-07-21 2017-07-21 B Purchase Clemmer James C

President and CEO

Executive Director
5,000 +5.8%
15.79
US$78,950 		5,000 +5.8% 15.79 US$78,950
2017-07-21 2017-07-21 B Purchase DONNELLY HOWARD W Non-Executive Director
5,000 +11.7%
15.72
US$78,600 		5,000 +11.7% 15.72 US$78,600
2017-07-21 2017-07-20 B Purchase Clemmer James C

President and CEO

Executive Director
20,000 +30.0%
15.64
US$312,800 		20,000 +30.0% 15.64 US$312,800
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
384,184 -50.2%
16.00
US$6,146,944 		384,184 -50.2% 16.00 US$6,146,944
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
508,869 -50.2%
16.00
US$8,141,904 		508,869 -50.2% 16.00 US$8,141,904
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
1,456,947 -50.2%
16.00
US$23,311,152 		1,456,947 -50.2% 16.00 US$23,311,152
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
384,184 -50.2%
16.00
US$6,146,944 		384,184 -50.2% 16.00 US$6,146,944
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
508,869 -50.2%
16.00
US$8,141,904 		508,869 -50.2% 16.00 US$8,141,904
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
1,456,947 -50.2%
16.00
US$23,311,152 		1,456,947 -50.2% 16.00 US$23,311,152
2016-11-22 2016-11-18 S Sale Avista Capital Partners GP, LLC Large shareholder
541,349 -34.8%
15.68
US$8,488,352 		541,349 -34.8% 15.68 US$8,488,352
2016-11-22 2016-11-18 S Sale Burgstahler David F Non-Executive Director Large shareholder
541,349 -34.8%
15.68
US$8,488,352 		541,349 -34.8% 15.68 US$8,488,352
2016-11-22 2016-11-18 S Sale Avista Capital Partners GP, LLC Large shareholder
1,549,945 -34.8%
15.68
US$24,303,138 		1,549,945 -34.8% 15.68 US$24,303,138
2016-11-22 2016-11-18 S Sale Burgstahler David F Non-Executive Director Large shareholder
1,549,945 -34.8%
15.68
US$24,303,138 		1,549,945 -34.8% 15.68 US$24,303,138
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
487,214 -23.9%
14.62
US$7,123,069 		487,214 -23.9% 14.62 US$7,123,069
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
367,836 -23.9%
14.62
US$5,377,762 		367,836 -23.9% 14.62 US$5,377,762
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
478,214 -23.5%
14.62
US$6,991,489 		478,214 -23.5% 14.62 US$6,991,489
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
367,836 -23.9%
14.62
US$5,377,762 		367,836 -23.9% 14.62 US$5,377,762
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
1,394,950 -23.9%
14.62
US$20,394,169 		1,394,950 -23.9% 14.62 US$20,394,169
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
1,394,950 -23.9%
14.62
US$20,394,169 		1,394,950 -23.9% 14.62 US$20,394,169
2016-05-09 2016-05-06 S Sale Greiner Charles R

VP - Global Franchise

Officer
3,508 -14.4%
12.31
US$43,183 		3,508 -14.4% 12.31 US$43,183
2016-04-25 2016-04-25 S Sale Trowbridge Stephen A

SVP and General Counsel

Officer
2,440 -7.5%
12.18
US$29,719 		2,440 -7.5% 12.18 US$29,719
2016-04-25 2016-04-21 S Sale Trowbridge Stephen A

SVP and General Counsel

Officer
10,500 -24.4%
12.33
US$129,465 		10,500 -24.4% 12.33 US$129,465
2015-02-19 2015-02-13 S Sale Richard Stark

SVP, GM - Oncology

Officer
18,100 -38.7%
18.53
US$335,393 		18,100 -38.7% 18.53 US$335,393
2014-10-21 2014-10-20 S Sale Greiner Charles R

VP - Global Franchise

Officer
3,298 -13.0%
15.63
US$51,548 		3,298 -13.0% 15.63 US$51,548
2013-11-15 2013-11-14 S Sale Greiner Charles R

VP - Global Finance

Officer
4,373 -15.9%
15.46
US$67,611 		4,373 -15.9% 15.46 US$67,611
2013-11-15 2013-11-13 S Sale Greiner Charles R

VP - Global Finance

Officer
2,392 -9.4%
15.40
US$36,842 		2,392 -9.4% 15.40 US$36,842
2013-10-21 2013-10-18 B Purchase BUCCI VINCENT Non-Executive Director
5,000 +6.1%
15.20
US$75,990 		5,000 +6.1% 15.20 US$75,990
2013-10-21 2013-10-17 S Sale DONNELLY HOWARD W Non-Executive Director
20,000 -55.8%
15.06
US$301,200 		20,000 -55.8% 15.06 US$301,200
2013-07-23 2013-07-22 B Purchase Gould Kevin J Non-Executive Director
2,700 +32.7%
12.00
US$32,400 		2,700 +32.7% 12.00 US$32,400
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
10,000 +333.3%
10.80
US$108,000 		10,000 +333.3% 10.80 US$108,000
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
35,000 +1166.7%
10.76
US$376,600 		35,000 +1166.7% 10.76 US$376,600
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
40,000 +103.4%
10.78
US$431,200 		40,000 +103.4% 10.78 US$431,200
2013-03-12 2013-03-12 B Purchase Meteny Dennis S Non-Executive Director
4,600 +26.5%
10.82
US$49,772 		4,600 +26.5% 10.82 US$49,772
2013-02-15 2013-02-14 B Purchase BUCCI VINCENT Non-Executive Director
2,000 +5.5%
12.17
US$24,332 		2,000 +5.5% 12.17 US$24,332
2013-01-14 2013-01-11 B Purchase Gould Kevin J Non-Executive Director
2,700 +48.6%
11.58
US$31,277 		2,700 +48.6% 11.58 US$31,277
2012-11-13 2012-11-05 B Purchase GOLD JEFFREY Non-Executive Director
1,000 +4.1%
10.56
US$10,560 		1,000 +4.1% 10.56 US$10,560
2012-11-09 2012-11-05 S Sale Richard Stark

SVP, GM - Oncology

Officer
3,160 -10.9%
10.36
US$32,738 		3,160 -10.9% 10.36 US$32,738
2012-07-18 2012-07-17 B Purchase DEVIVO JOSEPH

President and CEO

Executive Director
2,000 +5.6%
11.67
US$23,340 		2,000 +5.6% 11.67 US$23,340
2012-05-17 2012-05-16 S Sale Richard Stark

SVP, GM - Oncology

Officer
2,080 -9.0%
12.42
US$25,827 		2,080 -9.0% 12.42 US$25,827
2012-04-13 2012-04-12 B Purchase BUCCI VINCENT Non-Executive Director
4,000 +inf%
11.82
US$47,280 		4,000 +inf% 11.82 US$47,280
2012-04-12 2012-04-11 B Purchase Gould Kevin J Non-Executive Director
2,700 +inf%
11.72
US$31,636 		2,700 +inf% 11.72 US$31,636
2012-04-10 2012-04-10 B Purchase Kapusta Matthew C

SVP, Business Development

Officer
1,000 +6.7%
11.40
US$11,397 		1,000 +6.7% 11.40 US$11,397
2012-04-10 2012-04-09 B Purchase BUCCI VINCENT Non-Executive Director
2,000 +6.7%
11.80
US$23,596 		2,000 +6.7% 11.80 US$23,596
2012-04-10 2012-04-09 B Purchase DEVIVO JOSEPH

President and CEO

Executive Director
5,000 +16.1%
11.82
US$59,094 		5,000 +16.1% 11.82 US$59,094
Explore more

More insider trading research around AngioDynamics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America